ADPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adaptive Biotechnologies Corp (ADPT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows positive revenue growth and strong analyst support, the recent price decline, negative earnings trends, and lack of significant catalysts make it prudent to hold off on buying until clearer growth signals emerge.
The MACD is positive but contracting, RSI is neutral at 50.623, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 14.021, with support at 12.778 and resistance at 15.263.
Hedge funds are significantly increasing their holdings, and analysts have raised price targets following a strong Q4 performance. Revenue growth is robust at 51.04% YoY, and gross margin has improved to 73.98%.
The stock price has declined by 3.10% in regular trading and 0.92% post-market. Net income and EPS have dropped significantly YoY, and there are no recent news catalysts or congress trading activity. Options data shows a bearish sentiment with a high put-call volume ratio of 3.0.
In Q4 2025, revenue increased by 51.04% YoY to $71.68M, but net income dropped by 59.70% to -$13.58M, and EPS decreased by 60.87% to -$0.09. Gross margin improved to 73.98%, up 21.12% YoY.
Analysts are bullish, with multiple firms raising price targets to $21-$22 and maintaining Buy or Overweight ratings. They cite strong Q4 results, raised guidance, and growth drivers such as EMR integrations and new indications.
